Scilex (SCLX) Competitors $4.74 +0.13 (+2.82%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCLX vs. GLSI, FTLF, EDIT, THTX, LYEL, TARA, CGEN, SLS, NMRA, and SCPHShould you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Greenwich LifeSciences (GLSI), FitLife Brands (FTLF), Editas Medicine (EDIT), Theratechnologies (THTX), Lyell Immunopharma (LYEL), Protara Therapeutics (TARA), Compugen (CGEN), SELLAS Life Sciences Group (SLS), Neumora Therapeutics (NMRA), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Scilex vs. Greenwich LifeSciences FitLife Brands Editas Medicine Theratechnologies Lyell Immunopharma Protara Therapeutics Compugen SELLAS Life Sciences Group Neumora Therapeutics scPharmaceuticals Scilex (NASDAQ:SCLX) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking. Which has more volatility and risk, SCLX or GLSI? Scilex has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Is SCLX or GLSI more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to Scilex's net margin of -159.10%. Scilex's return on equity of 0.00% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Scilex-159.10% N/A -93.65% Greenwich LifeSciences N/A -185.12%-164.27% Which has stronger earnings & valuation, SCLX or GLSI? Greenwich LifeSciences has lower revenue, but higher earnings than Scilex. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScilex$56.59M0.58-$114.33M-$29.02-0.16Greenwich LifeSciencesN/AN/A-$8.89M-$1.20-8.42 Do analysts recommend SCLX or GLSI? Scilex presently has a consensus target price of $455.00, suggesting a potential upside of 9,499.16%. Greenwich LifeSciences has a consensus target price of $39.00, suggesting a potential upside of 286.14%. Given Scilex's higher probable upside, analysts plainly believe Scilex is more favorable than Greenwich LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to SCLX or GLSI? In the previous week, Greenwich LifeSciences had 5 more articles in the media than Scilex. MarketBeat recorded 8 mentions for Greenwich LifeSciences and 3 mentions for Scilex. Scilex's average media sentiment score of 0.96 beat Greenwich LifeSciences' score of 0.57 indicating that Scilex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Greenwich LifeSciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals and insiders believe in SCLX or GLSI? 69.7% of Scilex shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 7.7% of Scilex shares are owned by insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer SCLX or GLSI? Scilex received 4 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 86.67% of users gave Scilex an outperform vote while only 47.37% of users gave Greenwich LifeSciences an outperform vote. CompanyUnderperformOutperformScilexOutperform Votes1386.67% Underperform Votes213.33%Greenwich LifeSciencesOutperform Votes947.37% Underperform Votes1052.63% SummaryScilex beats Greenwich LifeSciences on 10 of the 17 factors compared between the two stocks. Get Scilex News Delivered to You Automatically Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCLX vs. The Competition Export to ExcelMetricScilexBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.08M$3.00B$5.56B$7.83BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-5.7130.4222.4818.48Price / Sales0.58498.92394.56103.59Price / CashN/A168.6838.1834.62Price / Book-4.313.206.774.25Net Income-$114.33M-$72.35M$3.22B$248.23M7 Day Performance7.00%1.46%1.48%0.89%1 Month Performance-42.98%8.79%3.99%3.53%1 Year Performance-84.17%-22.36%16.15%5.08% Scilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCLXScilex3.1967 of 5 stars$4.74+2.8%$455.00+9,499.2%-84.1%$32.08M$56.59M-5.7180Positive NewsGap UpHigh Trading VolumeGLSIGreenwich LifeSciences1.8436 of 5 stars$10.04+0.6%$39.00+288.4%-18.7%$133.27MN/A-12.553Short Interest ↑FTLFFitLife Brands4.1634 of 5 stars$14.42+0.8%$20.50+42.2%+8.9%$132.94M$64.47M17.0720Short Interest ↑EDITEditas Medicine4.1665 of 5 stars$1.58+2.6%$6.54+313.8%-68.3%$132.26M$32.31M-0.62230Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoverageTHTXTheratechnologiesN/A$2.87+3.6%N/A+118.5%$131.96M$88.67M-28.70140Short Interest ↑LYELLyell Immunopharma3.3977 of 5 stars$0.44-2.0%$1.00+126.8%-78.1%$130.24M$61,000.00-0.56270Upcoming EarningsNews CoveragePositive NewsTARAProtara Therapeutics2.2195 of 5 stars$3.52-18.5%$20.40+479.5%+17.4%$129.42MN/A-1.2530Analyst ForecastHigh Trading VolumeCGENCompugen2.0633 of 5 stars$1.44-2.7%$4.00+177.8%-17.1%$128.50M$27.86M72.0070Positive NewsGap UpSLSSELLAS Life Sciences Group0.7481 of 5 stars$1.41+0.7%N/A+25.0%$128.09M$1M-2.0410NMRANeumora Therapeutics3.1583 of 5 stars$0.76+0.7%$9.29+1,117.6%-91.4%$123.35MN/A-0.41108SCPHscPharmaceuticals3.7171 of 5 stars$2.45-2.4%$14.00+471.4%-43.0%$123.20M$36.33M-1.2930News CoveragePositive News Related Companies and Tools Related Companies GLSI Alternatives FTLF Alternatives EDIT Alternatives THTX Alternatives LYEL Alternatives TARA Alternatives CGEN Alternatives SLS Alternatives NMRA Alternatives SCPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCLX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SCLX Stock Free SCLX Stock Alerts